|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
1986-6-30
|
|
pubmed:abstractText |
Twenty-two patients with advanced measurable renal cell carcinoma were treated with AZQ 20 mg/m2 weekly for 4 weeks, followed by a 2-week rest. No complete or partial responses were observed among 15 fully evaluable patients. Stabilization was observed in eight individuals (range 8-27 weeks with a median of 12.5 weeks). Toxicity was primarily reversible myelosuppression. We conclude that AZQ administered at this dose and schedule has no significant activity against advanced renal cell carcinoma.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
0277-3732
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
9
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
126-8
|
|
pubmed:dateRevised |
2007-11-14
|
|
pubmed:meshHeading |
pubmed-meshheading:3717078-Adenocarcinoma,
pubmed-meshheading:3717078-Adult,
pubmed-meshheading:3717078-Antineoplastic Agents,
pubmed-meshheading:3717078-Aziridines,
pubmed-meshheading:3717078-Azirines,
pubmed-meshheading:3717078-Benzoquinones,
pubmed-meshheading:3717078-Drug Evaluation,
pubmed-meshheading:3717078-Female,
pubmed-meshheading:3717078-Humans,
pubmed-meshheading:3717078-Kidney Neoplasms,
pubmed-meshheading:3717078-Leukopenia,
pubmed-meshheading:3717078-Male,
pubmed-meshheading:3717078-Thrombocytopenia
|
|
pubmed:year |
1986
|
|
pubmed:articleTitle |
Phase II clinical evaluation of AZQ in renal cell carcinoma.
|
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.
|
